How will the current research advancements in long-acting ART affect clinicians’ ability to provide better care for their patients with HIV? The recent data show that the low uptake and adherence to PrEP may be largely due to the pill burden and potential stigma of daily dosing. How might the newer longer-acting PrEP regimens challenge this reluctance?

Post-test for CME credits: https://elit.dkbmed.com/issues/226/test

Hosted on Acast. See acast.com/privacy for more information.